Form 4: BIOADAPTIVES Director Mark Frissora Receives Convertible Preferred Stock as Board Compensation

BIOADAPTIVES, Inc. Director Mark P. Frissora was granted 713 shares of Series D Convertible Preferred Stock as compensation for board services, convertible into common stock at a 100:1 ratio.

Summary

• Mark P. Frissora, a Director and 10% Owner of BIOADAPTIVES, Inc. (BDPT), acquired 713 shares of Series D Convertible Preferred Stock on June 1, 2025.
• This acquisition was compensation for board services, as stipulated in a Board of Directors Agreement dated February 3, 2025.
• Each share of Series D Convertible Preferred Stock is convertible into 100 shares of common stock, subject to a 10% beneficial ownership limitation.
• Conversion of the preferred stock is restricted for six months from the issuance date, except in the case of liquidation, where it occurs immediately.
• Each Series D Convertible Preferred Stock share is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation.
• The right to convert the Series D Convertible Preferred Stock does not expire.
• Following this transaction, Mr. Frissora beneficially owns 46,347 shares of common stock directly and 713 shares of Series D Convertible Preferred Stock.

Sentiment

Score: 7

Explanation: The filing is a routine disclosure of director compensation, which is generally a positive sign of aligning interests. The terms of the preferred stock, including voting rights and conversion, are standard for such arrangements. There are no overtly negative or positive financial performance indicators, but the act of a director receiving equity compensation is mildly positive for governance and alignment.

Positives

• The issuance of Series D Convertible Preferred Stock as compensation aligns the director's financial interests with the long-term performance of BIOADAPTIVES, Inc.
• The director's continued acquisition of company securities demonstrates confidence in the company's future prospects.
• The significant voting rights (100 votes per share) associated with the preferred stock provide the director with substantial influence, potentially indicating strong governance involvement and commitment.

Negatives

• The potential future conversion of the Series D Convertible Preferred Stock into common stock could lead to dilution for existing common shareholders.
• The six-month restriction on conversion limits the immediate liquidity for the director from this specific compensation.

Risks

• Potential future dilution of common stock if the Series D Convertible Preferred Stock is converted, which could impact the per-share value for existing common shareholders.
• The 10% beneficial ownership limitation on conversion might restrict the director's ability to fully convert all shares at once, potentially affecting their liquidity or strategic flexibility.

Future Outlook

The document primarily reports a past transaction and does not provide explicit forward-looking statements or guidance regarding the company's operational or financial performance. However, the terms of the Series D Convertible Preferred Stock indicate future potential conversion into common stock and ongoing voting influence for the director.

Management Comments

• The document is a standard SEC Form 4 filing and does not contain direct quotes or paraphrased statements from company management, other than the signature of the reporting person, Mark P. Frissora.

Industry Context

This Form 4 filing reflects a common practice in corporate governance where directors receive equity compensation for their services. The use of convertible preferred stock with specific voting rights and conversion limitations is a structured approach to align director incentives with shareholder interests while managing potential dilution. This is typical across various industries, particularly for smaller-cap or developing companies.

Comparison to Industry Standards

• The compensation structure involving convertible preferred stock with a 100:1 conversion ratio and significant voting rights (100 votes per share) is a specific arrangement that can be more common in smaller or growth-oriented companies, such as BIOADAPTIVES, Inc., seeking to incentivize key personnel with equity while potentially managing immediate cash outflow.
• The 10% beneficial ownership limitation on conversion is a standard anti-dilution or control-management clause often seen in such agreements, aiming to prevent a single large conversion from disproportionately impacting the market.
• While a direct quantitative comparison to specific comparable companies or projects is not provided in the document, the general mechanism of equity compensation for directors is a standard practice across industries, though the specific terms of preferred stock can vary widely.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution from the conversion of preferred stock into common stock, but also benefit from aligned director incentives and strong voting influence of a key director.
• Management/Board: The compensation structure incentivizes the director's long-term commitment and performance.

Next Steps

• Potential future conversion of Series D Convertible Preferred Stock into common stock by Mark P. Frissora, subject to the six-month holding period and 10% beneficial ownership limitation.

Key Dates

Recommendation

Keywords

BIOADAPTIVES, BDPT, Form 4, Insider Transaction, Convertible Preferred Stock, Director Compensation, Equity Compensation, Corporate Governance, Beneficial Ownership, SEC Filing